T-Knife was founded by Elisa Kieback, Thomas Blankenstein.

Who are T-Knife's investors?

T-Knife's investors include Andera Partners, Versant Ventures, EQT Life Sciences, RA Capital, Sixty Degree Capital, Fidelity Investments.

How much funding has T-Knife raised?

T-Knife has disclosed $110M raised across 1 round.

Where is T-Knife headquartered?

T-Knife is headquartered in Berlin, DE.

T-Knife

Berlin, DE · 6 known investors

Find your way into T-Knife

608 people in our graph share verified history with the T-Knife team — schools, employers, funds. One of them is your warm intro.

Mojca Skoberneunlockedknows Elisa Kieback · together at Heidelberg University (overlapped)

×2knows the team · via University of California, Berkeley, Haas School of Business

×2knows the team · via Clue by Biowink

knows the team · via dkfz - German Cancer Research Center

knows the team · via Heidelberg University

knows the team · via University of St. Thomas

T-knife Therapeutics is a biopharmaceutical company developing T cell therapies to treat cancer, with an initial focus on solid tumors. It engineers fully human, tumor-specific T cell receptors along with novel CD8 coreceptors and switch receptors, using technology developed at the Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin.

Biotech Healthtech

Founders & leadership

Elisa Kieback inCTO and co-founderShe has expertise in T cell receptors and T cell-based cancer immunotherapies.

Thomas BlankensteinScientific Founder

Thomas SolowayChief Executive Officer

Camille Landis inChief Business Officer / Chief Financial OfficerCamille Landis is Chief Business Officer and Chief Financial Officer of T-Knife Therapeutics, bringing two decades of experience in biotechnology finance, corporate development, strategy, and commercial operations.

Peggy Sotiropoulou inChief Scientific OfficerPeggy Sotiropoulou is Chief Scientific Officer of T-Knife Therapeutics, a biopharmaceutical company developing T cell therapies for cancer. She has spent over 20 years working in oncology, immunology, and cell therapy, with experience advancing CAR-T, TCR-T, and next-generation cell therapy programs from concept to clinical development.

Investors · 6

Andera Partners✓ verifiedParis

Versant Ventures✓ verifiedSan Francisco · $250K – $5M

EQT Life Sciences✓ verifiedLuxembourg · $11M – $66M

RA CapitalBoston

Sixty Degree CapitalNorth York

Fidelity InvestmentsreportedBoston

Funding

SEC filings, press & company announcements

$110M disclosed across 1 round · 2021

$110MSeries BAug 2021 · 2 sources
Andera Partners
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

T-Knife secures $110m in series B - Global Venturingglobalventuring.com · Aug 2021

Andera Partners’ portfolio company T-knife raises USD110m in Series B funding - Private Equity Wireprivateequitywire.co.uk · Aug 2021

Frequently asked questions

What does T-Knife do?: T-knife Therapeutics is a biopharmaceutical company developing T cell therapies to treat cancer, with an initial focus on solid tumors. It engineers fully human, tumor-specific T cell receptors along with novel CD8 coreceptors and switch receptors, using technology developed at the Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin.
Who founded T-Knife?: T-Knife was founded by Elisa Kieback, Thomas Blankenstein.
Who are T-Knife's investors?: T-Knife's investors include Andera Partners, Versant Ventures, EQT Life Sciences, RA Capital, Sixty Degree Capital, Fidelity Investments.
How much funding has T-Knife raised?: T-Knife has disclosed $110M raised across 1 round.
Where is T-Knife headquartered?: T-Knife is headquartered in Berlin, DE.